Lorberboum-Galski H - Search Results

1

Mitochondrial Transfer Ameliorates Cognitive Deficits, Neuronal Loss, and Gliosis in Alzheimer's Disease Mice.

Nitzan K, Benhamron S, Valitsky M, Kesner EE, Lichtenstein M, Ben-Zvi A, Ella E, Segalstein Y, Saada A, Lorberboum-Galski H, Rosenmann H. Nitzan K, et al. Among authors: lorberboum galski h. J Alzheimers Dis. 2019;72(2):587-604. doi: 10.3233/JAD-190853. J Alzheimers Dis. 2019. PMID: 31640104

2

Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma.

Lichtenstein M, Ben-Yehudah A, Belostotsky R, Eaveri R, Sabag O, Grodzovski I, Lorberboum-Galski H. Lichtenstein M, et al. Int J Oncol. 2005 Jul;27(1):143-8. Int J Oncol. 2005. PMID: 15942653

3

C6ORF66 is an assembly factor of mitochondrial complex I.

Saada A, Edvardson S, Rapoport M, Shaag A, Amry K, Miller C, Lorberboum-Galski H, Elpeleg O. Saada A, et al. Am J Hum Genet. 2008 Jan;82(1):32-8. doi: 10.1016/j.ajhg.2007.08.003. Am J Hum Genet. 2008. PMID: 18179882 Free PMC article.

4

TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency.

Rapoport M, Saada A, Elpeleg O, Lorberboum-Galski H. Rapoport M, et al. Mol Ther. 2008 Apr;16(4):691-7. doi: 10.1038/mt.2008.4. Epub 2008 Feb 5. Mol Ther. 2008. PMID: 18362926 Free article.

5

Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.

Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H. Shteingart S, et al. Gut. 2009 Jun;58(6):790-8. doi: 10.1136/gut.2008.153981. Epub 2008 Oct 31. Gut. 2009. PMID: 18978179

6

IL2-caspase3 chimeric protein controls lymphocyte reactivity by targeted apoptosis, leading to amelioration of experimental autoimmune encephalomyelitis.

Irony-Tur-Sinai M, Lichtenstein M, Brenner T, Lorberboum-Galski H. Irony-Tur-Sinai M, et al. Int Immunopharmacol. 2009 Sep;9(10):1236-43. doi: 10.1016/j.intimp.2009.07.006. Epub 2009 Jul 22. Int Immunopharmacol. 2009. PMID: 19631295

7

IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway.

Grodzovski I, Lichtenstein M, Galski H, Lorberboum-Galski H. Grodzovski I, et al. Int J Cancer. 2011 Apr 15;128(8):1966-80. doi: 10.1002/ijc.25527. Int J Cancer. 2011. PMID: 20568105

8

α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease.

Israeli E, Yakunin E, Zarbiv Y, Hacohen-Solovich A, Kisos H, Loeb V, Lichtenstein M, Ben-Gedalya T, Sabag O, Pikarsky E, Lorberboum-Galski H, Sharon R. Israeli E, et al. PLoS One. 2011;6(5):e19622. doi: 10.1371/journal.pone.0019622. Epub 2011 May 18. PLoS One. 2011. PMID: 21611169 Free PMC article.

9

Eliminating the six N-terminal amino acids of the caspase 3 large subunit improved production of a biologically active IL2-Caspase3 chimeric protein.

Glantz Y, Sabag O, Lichtenstein M, Grodzovski I, Lorberboum-Galski H. Glantz Y, et al. Biotechnol Prog. 2012 Mar-Apr;28(2):573-80. doi: 10.1002/btpr.1515. Epub 2012 Mar 5. Biotechnol Prog. 2012. PMID: 22275241

10

Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells.

Marcus D, Lichtenstein M, Saada A, Lorberboum-Galski H. Marcus D, et al. Among authors: lorberboum galski h. Mol Med. 2013 Jul 24;19(1):124-34. doi: 10.2119/molmed.2012.00343. Mol Med. 2013. PMID: 23670274 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters